Exonics takeout, expanded CRISPR deal vault Vertex into neuromuscular diseases

Via a pair of deals totaling $420 million in upfront payments late Thursday, Vertex expanded into neuromuscular diseases and bolstered its gene editing capabilities by acquiring Exonics, broadening its partnership with CRISPR Therapeutics and hiring Audentes’ former CSO. The deals give the big biotech a new

Read the full 462 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE